ES2727334T3 - Métodos y ensayos basados en microARN para el osteosarcoma - Google Patents

Métodos y ensayos basados en microARN para el osteosarcoma Download PDF

Info

Publication number
ES2727334T3
ES2727334T3 ES12829323T ES12829323T ES2727334T3 ES 2727334 T3 ES2727334 T3 ES 2727334T3 ES 12829323 T ES12829323 T ES 12829323T ES 12829323 T ES12829323 T ES 12829323T ES 2727334 T3 ES2727334 T3 ES 2727334T3
Authority
ES
Spain
Prior art keywords
mir
seq
osteosarcoma
cells
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12829323T
Other languages
English (en)
Spanish (es)
Inventor
Takahiro Ochiya
Tomohiro Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3D Matrix Ltd
National Cancer Center Japan
National Cancer Center Korea
Original Assignee
3D Matrix Ltd
National Cancer Center Japan
National Cancer Center Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3D Matrix Ltd, National Cancer Center Japan, National Cancer Center Korea filed Critical 3D Matrix Ltd
Application granted granted Critical
Publication of ES2727334T3 publication Critical patent/ES2727334T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/02—Instruments for taking cell samples or for biopsy
    • A61B10/0233—Pointed or sharp biopsy instruments
    • A61B10/025—Pointed or sharp biopsy instruments for taking bone, bone marrow or cartilage samples
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
    • A61B5/4504—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/505—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of bone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Dentistry (AREA)
  • Optics & Photonics (AREA)
ES12829323T 2011-09-07 2012-09-07 Métodos y ensayos basados en microARN para el osteosarcoma Active ES2727334T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161531942P 2011-09-07 2011-09-07
US201261696981P 2012-09-05 2012-09-05
PCT/IB2012/002626 WO2013034989A2 (en) 2011-09-07 2012-09-07 Microrna-based methods and assays for osteosarcoma

Publications (1)

Publication Number Publication Date
ES2727334T3 true ES2727334T3 (es) 2019-10-15

Family

ID=47832670

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12829323T Active ES2727334T3 (es) 2011-09-07 2012-09-07 Métodos y ensayos basados en microARN para el osteosarcoma

Country Status (5)

Country Link
US (2) US9322016B2 (enExample)
EP (1) EP2753692B1 (enExample)
JP (1) JP6153932B2 (enExample)
ES (1) ES2727334T3 (enExample)
WO (1) WO2013034989A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905708B2 (en) 2011-09-07 2021-02-02 3-D Matrix, Ltd. MicroRNA-based methods and assays for osteocarcinoma
US11260072B2 (en) 2011-09-07 2022-03-01 3-D Matrix, Ltd. MicroRNA-based methods and assays for osteocarcinoma
US9315809B2 (en) * 2012-08-29 2016-04-19 City Of Hope Differentially expressed microRNA molecules for the treatment and diagnosis of cancer
CN105535995B (zh) * 2016-01-07 2018-12-07 赣南医学院第一附属医院 一种骨肉瘤诊疗制剂及其应用
KR101823605B1 (ko) 2016-12-02 2018-03-14 엘지전자 주식회사 태양 전지 및 이를 포함하는 태양 전지 패널
KR102588627B1 (ko) * 2017-03-08 2023-10-16 김성진 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
MX389585B (es) * 2017-05-08 2025-03-20 Unilever Ip Holdings B V Prevencion y/o tratamiento de una enfermedad inflamatoria de la piel
US20220096517A1 (en) * 2018-11-13 2022-03-31 Regulus Therapeutics Inc. MicroRNA Compounds and Methods for Modulating MIR-10B Activity
JP7607330B2 (ja) * 2021-04-30 2024-12-27 国立大学法人金沢大学 骨腫瘍の予後診断方法又は予後診断補助方法
CN113549691B (zh) * 2021-06-15 2023-03-31 上海长征医院 用于骨肉瘤分型和评估骨肉瘤预后的基因及其应用
CN113684279A (zh) * 2021-10-11 2021-11-23 核工业总医院 一种诊断骨肉瘤的引物组、试剂盒及检测方法
CN116179552A (zh) * 2023-03-28 2023-05-30 广东明珠生物技术有限公司 抑制人FAM86B1基因表达的siRNA及FAM86B1低表达的细胞系

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
US20090005336A1 (en) 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20110021609A1 (en) * 2008-02-28 2011-01-27 The Ohio State University Research Foundation MicroRNA Signatures Associated with Cytogenetics and Prognosis in Acute Myeloid Leukemia (AML) and Uses Thereof
AU2009283906A1 (en) * 2008-08-19 2010-02-25 Maine Institute For Human Genetics And Health Micro RNA and Neurofibromatosis Type 1 in diagnosis and therapy
WO2010136846A1 (en) 2009-05-25 2010-12-02 Carola Ponzetto Differentiation therapy for sarcomas
CN102080086B (zh) * 2009-12-01 2012-12-26 中国科学院上海药物研究所 人miR-133a反义核酸及其应用
US8889649B2 (en) * 2010-11-12 2014-11-18 National University Corporation Ehime University Composition containing antisense oligonucleotide to micro RNA

Also Published As

Publication number Publication date
EP2753692A4 (en) 2015-05-06
US20160355809A1 (en) 2016-12-08
WO2013034989A3 (en) 2013-06-06
JP2014527807A (ja) 2014-10-23
EP2753692B1 (en) 2019-03-27
US20140243392A1 (en) 2014-08-28
WO2013034989A2 (en) 2013-03-14
JP6153932B2 (ja) 2017-06-28
US9322016B2 (en) 2016-04-26
EP2753692A2 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
ES2727334T3 (es) Métodos y ensayos basados en microARN para el osteosarcoma
Wu et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
CN109312341B (zh) 微小rna及其使用方法
ES2966571T3 (es) Biogénesis de miARN en exosomas para diagnóstico y terapia
Amponsah et al. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer
Wu et al. miR-362-5p inhibits proliferation and migration of neuroblastoma cells by targeting phosphatidylinositol 3-kinase-C2β
US9642821B2 (en) MiR-182 in the diagnosis and treatment of cancer
Chen et al. Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis
US20160346311A1 (en) Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
Huang et al. CircRNA_000864 upregulates B-cell translocation gene 2 expression and represses migration and invasion in pancreatic cancer cells by binding to miR-361-3p
EP3263714B1 (en) Method for diagnosing brain metastasis
Ghosh et al. MicroRNA-874–mediated inhibition of the major G1/S phase cyclin, CCNE1, is lost in osteosarcomas
JP2013514277A (ja) 糖尿病におけるｍｉＲＮＡに関連する組成物と方法
CN104918659A (zh) 结肠癌的治疗和诊断
Lim et al. Suppression of oral carcinoma oncogenic activity by microRNA-203 via down-regulation of SEMA6A
EP2812449B1 (en) USE OF miR-199a-5p, TARGETS AND/OR INHIBITORS THEREOF FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF FIBROPROLIFERATIVE DISORDERS
ES2828510T3 (es) Agente terapéutico para tratar un cáncer en el que NRF2 está estabilizado
EP2886122B1 (en) Agent for treating cancer
WO2015133522A1 (ja) 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
US10905708B2 (en) MicroRNA-based methods and assays for osteocarcinoma
US11260072B2 (en) MicroRNA-based methods and assays for osteocarcinoma
JPWO2011125245A1 (ja) ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法
Shao et al. Upregulation of has_circ_0008389 promotes esophageal squamous cell carcinoma progression via miR-761 sponging and P2RY2 mRNA stabilization
EP3545091A1 (en) Agents for the treatment of patients with nsclc and methods to predict response
Fellenberg et al. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer